This study was followed by the DESTINY‐Breast 04 phase III randomized study comparing T‐DXd with the investigator's choice of chemotherapy in HER2‐low breast cancer, which recently met its primary endpoints. The gene discussed is ERBB2; the disease is breast cancer.